Objective To investigate the epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome (SFTS),and to improve the understanding and cure rate of SFTS. Method The epidemiological and clinical data of 992 SFTS patients in Xinyang City from 2018 to 2020 were retrospectively analyzed. Results Among 992 cases of SFTS,23.19% were severe cases,and the average fatality rate was 14.95%.There was significant difference in the fatality rate of SFTS from 2018 to 2020 (χ2=49.852,P＜0.001).There were 395 males and 597 females,with a male/female ratio of 1:1.51.The number of patients aged 60-69 was the largest,accounting for 35.08%,and farmers were the main occupation,accounting for 93.85%.The proportion of SFTS cases in Shangcheng and Guangshan County in mountainous and hilly areas accounted for 51.31% of the total cases.96.16% had a history of outdoor activities or field work before onset,25.91% had a clear tick bite history,and 24.29% had onset in May.Clinical symptoms include fever,fatigue,poor appetite,nausea,systemic soreness and inguinal lymph node enlargement and tenderness.Blood routine showed decreased white blood cell count and thrombocytopenia.Proteinuria,hematuria,prolongation of coagulation time and change of biochemical indexes were the main factors. Conclusion SFTS is a highly fatal viral infectious disease.The patients have obvious epidemic history and typical clinical features.
Key words
Severe fever with thrombocytopenia syndrome /
Severe fever with thrombocytopenia syndrome virus /
Epidemiological features /
Clinical features
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 孙立平,童巧霞,揭盛华.发热伴血小板减少综合征研究进展[J].中国媒介生物学及控制杂志,2014,25(1):87-89.
[2] Yu XJ,Liang MF,Zhang SY,et al.Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China[J].New England Journal of Medicine,2011,364(16):1523-1532.
[3] 于海峰,王永梅.发热伴血小板减少综合征患者的临床特点与生存状况[J].检验医学与临床,2017,14(21):3208-3210.
[4] 张文宏,翁心华.新发布尼亚病毒引起的发热伴血小板减少综合征:老问题,新发现[J].中华传染病杂志,2012,30(5):257-258.
[5] 中华人民共和国卫生部.发热伴血小板减少综合征防治指南(2010版)[J].中华临床感染病杂志,2011,4(4):193-194.
[6] Liu K,Cui N,Fang LQ,Wang Bing-Jun,,et al.Epidemiologic features and environmental risk factors of severe fever with thrombocytopenia syndrome,Xinyang,China.[J].PLoS neglected tropical diseases,2014,8(5):e2820.
[7] 张兰,袁春,袁义美.新型布尼亚病毒重复感染病例临床特点分析[J].安徽预防医学杂志,2021,27(1):51-54.
[8] 韩亚萍,董莉,孔练花,等.病毒载量和细胞因子在发热伴血小板减少综合征致病机制中的作用[J].中华传染病杂志,2014,32(9):538-544.
[9] Liu W,Lu QB,Cui N,et al.Case-Fatality Ratio and Effectiveness of Ribavirin Therapy Among Hospitalized Patients in China Who Had Severe Fever With Thrombocytopenia Syndrome[J].Clinical Infectious Diseases,2013,57(9):1292-1299.
[10] Shiraki K,Daikoku T.Favipiravir,an anti-influenza drug against life-threatening RNA virus infections[J].Pharmacol Ther,2020:107512.
[11] Furuta Y,Takahashi K,Shiraki K,et al.,et al.T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections[J].Antiviral Research,2009,82(3):95-102.
[12] Jin ZN,Tucker K,Lin XY,et al.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.[J].Antimicrobial agents and chemotherapy,2015,59(12):7504-7516.
[13] Tani H,Fukuma A,Fukushi S,et al.Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus[J].2016,1(1): e00061-e00015.
PDF(958 KB)
